Live feed11:22:00·376dPRReleasevia QuantisnowPress Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory studyByQuantisnow·Wall Street's wire, on your screen.REGN· Regeneron Pharmaceuticals Inc.Health Care
